Publications & Posters

BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade

https://doi.org/10.1016/j.jid.2018.12.024

ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition

https://doi.org/10.1182/blood-2018-05-849554

Blocking colony stimulating factor 1 receptor (CSF-1R) and tropomyosin receptor kinase A (TrkA) improves the antitumor efficacy of immune checkpoint blockade

https://www.jimmunol.org/content/200/1_Supplement/122.15/tab-article-info

Phase 1b/2a Study of PLX51107, a Small Molecule BET Inhibitor, in Subjects with Advanced Hematological Malignancies and Solid Tumors

Download PDF

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor

https://doi.org/10.1158/2159-8290.CD-17-0902

b2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer

https://doi.org/10.1016/j.ccell.2017.11.007

Resistance to BET inhibitors involves the Wnt/β-catenin Pathway in Uveal Melanoma

Download PDF

Nerve growth factor promotes gastric tumorigenesis through aberrant cholinergic signaling

https://doi.org/10.1016/j.ccell.2016.11.005

Response and Resistance to Bromodomain Inhibition in Acute Myeloid Leukemia

Download PDF

Broad Anti-Tumor Activity of a Novel BET Bromodomain Inhibitor

Download PDF